Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Intra-peritoneal Cantrixil in Ovarian Cancer
NCT02903771Phase 1Completed
- Sponsor
- Kazia Therapeutics
- Start
- Dec 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of cantrixil in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Kazia Therapeutics. Primary endpoints: Maximum Tolerated Dose, Pharmacokinetic Profile Cycle 1 and 1 more. Started Dec 2016; status: completed.
02
Drugs
cantrixil
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02903771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903771.